Depomed, Inc. s trend and data analysis indicates that the stock price has dropped -14.66% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -36.8% . Looking at the past 52 week period, the stock price is up at 18.65% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Depomed, Inc. has a positive value of 4.09 compared to overall market.Depomed, Inc. is having a Relative Strength Index of 42.55 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Stocks of Depomed, Inc. (NASDAQ:DEPO) rallied by 0.32% during the past week but lost 4.19% on a 4-week basis. The company has outperformed the S&P 500 by 0.08% in the past week but underperformed the index by 5.28% in the last 4 weeks.
Company shares have received an average consensus rating of Hold for the current week Depomed, Inc. (NASDAQ:DEPO) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.33 points or 2.05% at $15.78 with 1,675,711 shares getting traded. Post opening the session at $16.06, the shares hit an intraday low of $15.69 and an intraday high of $16.09 and the price was in this range throughout the day. The company has a market cap of $980 million and the number of outstanding shares has been calculated to be 62,099,557 shares. The 52-week high of Depomed, Inc. (NASDAQ:DEPO) is $27.0199 and the 52-week low is $12.25.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Depomed Inc was Downgraded by Mizuho on Feb 14, 2017 to Neutral, Lowers Price Target to $ 17 from a previous price target of $24 .
Company has reported several Insider transactions to the SEC, on Nov 15, 2016, August J Moretti (Chief Financial Officer & SVP) sold 5,000 shares at 20.84 per share price.On Sep 22, 2016, Thadd M Vargas (Senior VP, BD) sold 11,250 shares at 25.00 per share price.
Depomed Inc Last issued its quarterly earnings results on Feb 21, 2017. The company reported $0.48 EPS for the quarter, beating the analyst consensus estimate by $ 0.12. Analyst had a consensus of $0.36. The company had revenue of $123.90 million for the quarter, compared to analysts expectations of $123.00 million. The companys revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.16 EPS.
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once- daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin XR extended-release tablets have been approved by the FDA for the once-daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once-daily Glumetza has been approved for use in adults with type two diabetes and is currently being marketed in the United States and Canada. The company is currently evaluating Gabapentin GR for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy, and menopausal hot flashes.